TARGETING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF): SMALL-MOLECULE INHIBITORS AND THERAPEUTIC STRATEGIES FOR IMMUNE DISORDERS AND CANCER

Prithiviraj Nagarajan; Leena Rajathy Port Louis; Kumar Rangarajalu

doi:10.46903/gjms/22.03.1441

TARGETING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF): SMALL-MOLECULE INHIBITORS AND THERAPEUTIC STRATEGIES FOR IMMUNE DISORDERS AND CANCER

Prithiviraj Nagarajan, Leena Rajathy Port Louis, Kumar Rangarajalu

Abstract

Macrophage Migration Inhibitory Factor (MIF) is a critical cytokine implicated in various human disorders, with significant roles in innate and acquired immunity and inflammatory diseases. Recent investigations have linked MIF to the pathophysiology of cancer. Extensive research has been dedicated to studying its structure and actions, leading to its classification as both an enzyme and a hormone. Its isomerase enzymatic activity is exciting, which has sparked enthusiasm for developing specific small-molecule inhibitors targeting this unique enzymatic function to treat inflammatory illnesses potentially. While there is growing awareness of MIF’s importance in inflammation and cancer, the availability of adequate and extensively studied MIF inhibitors for relevant disease models remains limited. Advancing drug discovery necessitates the development of highly potent and selective small-molecule MIF inhibitors, along with rigorous validation in disease models. Our review article comprehensively summarizes recent progress recognizing MIF as a pharmaceutical target for inflammatory conditions and cancer. Furthermore, it highlights promising areas for future research in this domain and outlines recent advancements in identifying and designing small-molecule MIF inhibitors. These efforts aim to facilitate the development of novel therapies that target MIF and have the potential to address various disease conditions associated with its dysregulation.

Keywords

Cancer; Cytokine; Inflammatory diseases; Macrophage migration inhibitory factor (MIF); Small-molecule inhibitors; Therapeutic potential.

Full Text:

PDF

References

Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science. 1996;153:3.

David J. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A. 1966;56:6. https://doi.org/10.1073/pnas.56.1.72.

Nishihira J, Koyama Y, Mizue Y. Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine. 1998;10:199-205. https://doi.org/10.1006/cyto.1997.0276.

Rossi AG, Haslett C, Hirani N, Greening AP, Rahman I, Metz CN, et al. Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest. 1998;101:2869-2874. https://doi.org/10.1172/JCI1524.

Imamura K, Nishihira J, Suzuki M, Yasuda K, Sasaki S, Kusunoki Y, et al. Identification and immunohistochemical localization of macrophage migration inhibitory factor in human kidney. Biochem Mol Biol Int. 1996;40:1233-1242. https://doi.org/10.1080/15216549600201883.

Shimizu T. Role of macrophage migration inhibitory factor (MIF) in the skin. J Dermatol Sci. 2005;37:65-73. https://doi.org/10.1016/j.jdermsci.2004.08.007.

Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A. 1996;93:7849-7854. https://doi.org/10.1073/pnas.93.15.7849.

Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med. 1994;179:1895-1902. https://doi.org/10.1084/jem.179.6.1895.

Daryadel A, Grifone RF, Simon HU, Yousefi S. Apoptotic neutrophils release macrophage migration inhibitory factor upon stimulation with tumor necrosis factor-alpha. J Biol Chem. 2006;281:27653-27661. https://doi.org/10.1074/jbc.M604051200.

Pan JH, Sukhova GK, Yang JT, Wang B, Xie T, Fu H, et al. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2004;109:3149-3153. https://doi.org/10.1161/01.CIR.0000134704.84454.D2.

Donnelly SC, Haslett C, Reid PT, Grant IS, Wallace WA, Metz CN, et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med. 1997;3:320-323. https://doi.org/10.1038/nm0397-320.

Morand EF, Leech M, Weedon H, Metz CN, Bucala R, Smith MD. Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. Rheumatology (Oxford). 2002;41:558-562. https://doi.org/10.1093/rheumatology/41.5.558.

Bucala R, Donnelly SC. Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity. 2007;26:281-285. https://doi.org/10.1016/j.immuni.2007.03.005.

Rosengren E, Bucala R, Aman P, Jacobsson L, Odh G, Metz CN, Rorsman H. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med. 1996;2:143-149. https://doi.org/10.1007/BF03402210.

Sun HW, Swope M, Cinquina C, Bedarkar S, Bernhagen J, Bucala R, Lolis E. The subunit structure of human macrophage migration inhibitory factor: evidence for a trimer. Protein Eng. 1996;9:631-635. https://doi.org/10.1093/protein/9.8.631.

Baugh JA, Bucala R. Macrophage migration inhibitory factor. Crit Care Med. 2002;30(Suppl 1):S27-S35. https://doi.org/10.1097/00003246-200201001-00004.

Mischke R, Gessner A, Kapurniotu A, Juttner S, Kleemann R, Brunner H, Bernhagen J. Structure activity studies of the cytokine macrophage migration inhibitory factor (MIF) reveal a critical role for its carboxy terminus. FEBS Lett. 1997;414:226-232. https://doi.org/10.1016/S0014-5793(97)01039-9.

El-Turk F, Cascella M, Ouertatani-Sakouhi H, Narayanan RL, Leng L, Bucala R, et al. The conformational flexibility of the carboxy terminal residues 105-114 is a key modulator of the catalytic activity and stability of macrophage migration inhibitory factor. Biochemistry. 2008;47:10740-10756. https://doi.org/10.1021/bi800603x.

Stamps SL, Fitzgerald MC, Whitman CP. Characterization of the role of the amino-terminal proline in the enzymatic activity catalyzed by macrophage migration inhibitory factor. Biochemistry. 1998;37:10195-10202. https://doi.org/10.1021/bi9806955.

Swope M, Sun HW, Blake PR, Lolis E. Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor. EMBO J. 1998;17:3534-3541. https://doi.org/10.1093/emboj/17.13.3534.

Bendrat K, Al-Abed Y, Callaway DJ, Peng T, Calandra T, Metz CN, Bucala R. Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry. 1997;36:15356-15362. https://doi.org/10.1021/bi971153a.

Lubetsky JB, Swope M, Dealwis C, Blake P, Lolis E. Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity. Biochemistry. 1999;38:7346-7354. https://doi.org/10.1021/bi990306m.

Petrovsky N, Socha L, Silva D, Grossman AB, Metz C, Bucala R. Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator. Immunol Cell Biol. 2003;81:137-143. https://doi.org/10.1046/j.0818-9641.2002.01148.x.

Bloom J, Metz C, Nalawade S, Casabar J, Cheng KF, He M, et al. Identification of iguratimod as an inhibitor of macrophage migration inhibitory factor (MIF) with steroid-sparing potential. J Biol Chem. 2016;291:26502-26514. https://doi.org/10.1074/jbc.M116.743328.

Harris J, Vanpatten S, Deen NS, Al-Abed Y, Morand EF. Rediscovering MIF: new tricks for an old cytokine. Trends Immunol. 2019;40:447-462. https://doi.org/10.1016/j.it.2019.03.002.

Rosengren E, Åman P, Thelin S, Hansson C, Ahlfors S, Björk P, et al. The macrophage migration inhibitory factor MIF is a phenyl pyruvate tautomerase. FEBS Lett. 1997;417:85-88. https://doi.org/10.1016/S0014-5793(97)01261-1.

Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature. 2000;408:211-216. https://doi.org/10.1038/35041591.

Kleemann R, Kapurniotu A, Frank RW, Gessner A, Mischke R, Flieger O, Juttner S, Brunner H, Bernhagen J. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol. 1998;280:85-102. https://doi.org/10.1006/jmbi.1998.1864.

Matsunaga J, Sinha D, Pannell L, Santis C, Solano F, Wistow GJ, Hearing VJ. Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines. J Biol Chem. 1999;274:3268-3271. https://doi.org/10.1074/jbc.274.6.3268.

Al-Abed Y, Dabideen D, Aljabari B, Valster A, Messmer D, Ochani M, et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem. 2005;280:36541-36544. https://doi.org/10.1074/jbc.C500243200.

Winner M, Meier J, Zierow S, Rendon BE, Crichlow GV, Riggs R, et al. A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res. 2008;68:7253-7257. https://doi.org/10.1158/0008-5472.CAN-07-6227.

Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006;124:823-835. https://doi.org/10.1016/j.cell.2006.02.016.

Bini L, Magi B, Marzocchi R, Arcuri F, Tripodi S, Cintorino M, et al. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis. 1997;18:2832-2841. https://doi.org/10.1002/elps.1150181519.

Armstrong ME, Gantier M, Li L, Chung WY, McCann A, Baugh JA, Donnelly SC. Small interfering RNAs induce macrophage migration inhibitory factor production and proliferation in breast cancer cells via a double-stranded RNA-dependent protein kinase-dependent mechanism. J Immunol. 2008;180:7125-7133. https://doi.org/10.4049/jimmunol.180.11.7125.

Wilson JM, Coletta PL, Cuthbert RJ, Scott N, MacLennan K, Hawcroft G. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology. 2005;129:1485-1503. https://doi.org/10.1053/j.gastro.2005.07.061.

Akbar SM, Abe M, Murakami H, Tanimoto K, Kumagi T, Yamashita Y, et al. Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. Cancer Lett. 2001;171:125-132. https://doi.org/10.1016/S0304-3835(01)00606-1.

Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka-Akita H, et al. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer. 2000;89:334-341. https://doi.org/10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N.

Bin Q, Johnson BD, Schauer DW, Casper JT, Orentas RJ. Production of macrophage migration inhibitory factor by human and murine neuroblastoma. Tumour Biol. 2002;23:123-129. https://doi.org/10.1159/000064028.

Meyer-Siegler PBK. Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology. 1996;48:448-452. https://doi.org/10.1016/S0090-4295(96)00207-5.

Xia HH, Lam SK, Chan AO, Lin MC, Kung HF, Ogura K, et al. Macrophage migration inhibitory factor stimulated by Helicobacter pylori increases proliferation of gastric epithelial cells. World J Gastroenterol. 2005;11:1946-1950. https://doi.org/10.3748/wjg.v11.i13.1946.

Meyer-Siegler KL, Iczkowski KA, Vera PL. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer. 2005;5:73. https://doi.org/10.1186/1471-2407-5-73.

Fingerle-Rowson G, Petrenko O, Metz CN, Forsthuber TG, Mitchell R, Huss R, et al. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A. 2003;100:9354-9359. https://doi.org/10.1073/pnas.1533295100.

Xu X, Wang B, Ye C, Yao C, Lin Y, Huang X, et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett. 2008;261:147-157. https://doi.org/10.1016/j.canlet.2007.11.028.

Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, Honig A, Hausler S, et al. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol. 2008;180:7338-7348. https://doi.org/10.4049/jimmunol.180.11.7338.

Martin J, Duncan FJ, Keiser T, Shin S, Kusewitt DF, Oberyszyn TM, et al. Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet-B (UVB)-induced nonmelanoma skin cancer (NMSC). FASEB J. 2009;23:720-730. https://doi.org/10.1096/fj.08-119628.

Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hültner L, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med. 2000;6:164-170. https://doi.org/10.1038/72262.

Mikulowska A, Metz CN, Bucala R, Holmdahl R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol. 1997;158:5514-5517. https://doi.org/10.4049/jimmunol.158.11.5514.

Amano T, Nishihira J, Miki I. Blockade of macrophage migration inhibitory factor (MIF) prevents the antigen-induced response in a murine model of allergic airway inflammation. Inflamm Res. 2007;56:24-31. https://doi.org/10.1007/s00011-007-5184-9.

Ohkawara T, Nishihira J, Takeda H, Hige S, Kato M, Sugiyama T, et al. Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology. 2002;123:256-270. https://doi.org/10.1053/gast.2002.34236.

Brown FG, Nikolic-Paterson DJ, Hill PA, Isbel NM, Dowling J, Metz CM, et al. Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J Am Soc Nephrol. 2002;13 Suppl 1. https://doi.org/10.1681/ASN.V13suppl_1s7

Xu L, Li Y, Sun H, Zhen X, Qiao C, Tian S, et al. Current developments of macrophage migration inhibitory factor (MIF) inhibitors. Drug Discov Today. 2013;18:592-600. https://doi.org/10.1016/j.drudis.2012.12.013.

Kok T, Wasiel AA, Cool RH, Melgert BN, Poelarends GJ, Dekker FJ. Small-molecule inhibitors of macrophage migration inhibitory factor (MIF) as an emerging class of therapeutics for immune disorders. Drug Discov Today. 2018;23:1910-1918. https://doi.org/10.1016/j.drudis.2018.06.017.

Trivedi-Parmar V, Jorgensen WL. Advances and insights for small molecule inhibition of macrophage migration inhibitory factor. J Med Chem. 2018;61:8104-8119. https://doi.org/10.1021/acs.jmedchem.8b00589.

Mawhinney L, Armstrong ME, O'Reilly C, Bucala R, Leng L, Fingerle-Rowson G, et al. Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer. Mol Med. 2015;20:729-735. https://doi.org/10.2119/molmed.2014.00136.

Choudhary S, Hegde P, Pruitt JR, Sielecki TM, Choudhary D, Scarpato K, et al. Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis. Carcinogenesis. 2013;34:2891-2899. https://doi.org/10.1093/carcin/bgt239.

Liu H, Chen G, Zhang W, Zhu JY, Lin ZQ, Gong ZC, et al. Overexpression of macrophage migration inhibitory factor in adenoid cystic carcinoma: correlation with enhanced metastatic potential. J Cancer Res Clin Oncol. 2013;139:287-295. https://doi.org/10.1007/s00432-012-1330-z.

Ioanou K, Cheng KF, Crichlow GV, Birmpilis AI, LoLis EJ, Tsitsilonis OE, et al. ISO66, a novel inhibitor of macrophage migration inhibitory factor, shows efficacy in melanoma and colon cancer models. Int J Oncol. 2014;45:1457-1468. https://doi.org/10.3892/ijo.2014.2551.

Brown KK, Blaikie FH, Smith RA, Tyndall JD, Lue H, Bernhagen J, et al. Direct modification of the proinflammatory cytokine macrophage migration inhibitory factor by dietary isothiocyanates. J Biol Chem. 2009;284:32425-32433. https://doi.org/10.1074/jbc.M109.047092.

Dickerhof N, Magon NJ, Tyndall JD, Kettle AJ, Hampton MB. Potent inhibition of macrophage migration inhibitory factor (MIF) by myeloperoxidase-dependent oxidation of epicatechins. Biochem J. 2014;462:303-314. https://doi.org/10.1042/BJ20140612.

Spencer ES, Dale EJ, Gommans AL, Rutledge MT, Vo CT, Nakatani Y, et al. Multiple binding modes of isothiocyanates that inhibit macrophage migration inhibitory factor. Eur J Med Chem. 2015;93:501-510. https://doi.org/10.1016/j.ejmech.2015.02.012.

Bloom J, Sun S, Al-Abed Y. MIF, a controversial cytokine: a review of structural features, challenges, and opportunities for drug development. Expert Opin Ther Targets. 2016;20:1463-1475. https://doi.org/10.1080/14728222.2016.1251582.

Sakai Y, Masamune A, Satoh A, Nishihira J, Yamagiwa T, Shimosegawa T. Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis. Gastroenterology. 2003;124:725-736. https://doi.org/10.1053/gast.2003.50099.

Matsuda N, Nishihira J, Takahashi Y, Kemmotsu O, Hattori Y. Role of macrophage migration inhibitory factor in acute lung injury in mice with acute pancreatitis complicated by endotoxemia. Am J Respir Cell Mol Biol. 2006;35:198-205. https://doi.org/10.1165/rcmb.2005-0272OC.

Sparkes A, De Baetselier P, Brys L, Cabrito I, Sterckx YG, Schoonooghe S, et al. Novel half-life extended anti-MIF nanobodies protect against endotoxic shock. FASEB J. 2018;32:3411-3422. https://doi.org/10.1096/fj.201701189R.

Hussain F, Freissmuth M, Völkel D, Thiele M, Douillard P, Antoine G, et al. Human anti-macrophage migration inhibitory factor antibodies inhibit growth of human prostate cancer cells in vitro and in vivo. Mol Cancer Ther. 2013;12:1223-1234. https://doi.org/10.1158/1535-7163.MCT-12-0988.

Mahalingam D, Patel MR, Sachdev JC, Hart LL, Halama N, Ramanathan RK, et al. Phase I study of imalumab (BAX69), a fully human recombinant anti-oxidized macrophage migration inhibitory factor antibody in advanced solid tumors. Br J Clin Pharmacol. 2020;86:1836-1848. https://doi.org/10.1111/bcp.14289.

Stein R, Qu Z, Cardillo TM, Chen S, Rosario A, Horak ID, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood. 2004;104:3705-3711. https://doi.org/10.1182/blood-2004-03-0890.

Stein R, Smith MR, Chen S, Zalath M, Goldenberg DM. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. Clin Cancer Res. 2009;15:2808-2817. https://doi.org/10.1158/1078-0432.CCR-08-1953.

Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, et al. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol. 2013;163:478-486. https://doi.org/10.1111/bjh.12565.

Wallace DJ, Wegener WA, Horne H, Goldenberg DM. CT-01 Phase IB study of IMMU-115 (humanised ANTI-CD74 antibody) targeting antigen presenting cells in patients with systemic lupus erythematosus (SLE). Lupus Sci Med. 2016;3:A37. https://doi.org/10.1136/lupus-2016-000179.73.

Steinberg M, Silva M. Plerixafor: a chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma. Clin Ther. 2010;32:821-843. https://doi.org/10.1016/j.clinthera.2010.05.007.

Goldstein LJ, Perez RP, Yardley D, Han LK, Reuben JM, Gao H, et al. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin inoperable HER-2-negative breast cancer. Breast Cancer Res. 2020;22:4. https://doi.org/10.1186/s13058-019-1243-8.

Farr L, Ghosh S, Moonah S. Role of MIF cytokine/CD74 receptor pathway in protecting against injury and promoting repair. Front Immunol. 2020;11:1273. https://doi.org/10.3389/fimmu.2020.01273.

Harper JM, Wilkinson JE, Miller RA. Macrophage migration inhibitory factor-knock out mice are long lived and respond to caloric restriction. FASEB J. 2010;24:2436-2442. https://doi.org/10.1096/fj.09-152223.

Zhu C, Liu Y, Song Y, Wang Q, Liu Y, Yang S, et al. Deletion of macrophage migration inhibitory factor ameliorates inflammation in a mouse model of severe acute pancreatitis. Biomed Pharmacother. 2020;125:109919. https://doi.org/10.1016/j.biopha.2020.109919.

Kindt N, Preillon J, Kaltner H, Gabius HJ, Chevalier D, Rodriguez A, et al. Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. J Cancer Res Clin Oncol. 2013;139:727-737. https://doi.org/10.1007/s00432-013-1375-7.

Funamizu N, Hu C, Lacy C, Schetter A, Zhang G, He P, et al. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness, and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. Int J Cancer. 2013;132:785-794. https://doi.org/10.1002/ijc.27736.

Cisneros JA, Robertson MJ, Valhondo M, Jorgensen WL. A fluorescence polarization assay for binding to macrophage migration inhibitory factor and crystal structures for complexes of two potent inhibitors. J Am Chem Soc. 2016;138:8630-8. https://doi.org/10.1021/jacs.6b04910.

DOI: https://doi.org/10.46903/gjms/22.03.1441